These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22753833)

  • 1. Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?
    Loddenkemper R; Sotgiu G; Mitnick CD
    Eur Respir J; 2012 Jul; 40(1):9-11. PubMed ID: 22753833
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.
    Rouzier VA; Oxlade O; Verduga R; Gresely L; Menzies D
    Int J Tuberc Lung Dis; 2010 Oct; 14(10):1316-22. PubMed ID: 20843424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis: cost of illness in Germany.
    Diel R; Rutz S; Castell S; Schaberg T
    Eur Respir J; 2012 Jul; 40(1):143-51. PubMed ID: 22267754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost of multi drug resistance tuberculosis in Germany.
    Diel R; Nienhaus A; Lampenius N; Rüsch-Gerdes S; Richter E
    Respir Med; 2014 Nov; 108(11):1677-87. PubMed ID: 25443398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effective control of drug-resistant TB: listening to other voices.
    Portero JL; Rubio M
    PLoS Med; 2006 Dec; 3(12):e542. PubMed ID: 17194207
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost analysis of different types of tuberculosis patient at tuberculosis centers in Thailand.
    Kamolratanakul P; Hiransuthikul N; Singhadong N; Kasetjaroen Y; Akksilp S; Lertmaharit S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):321-30. PubMed ID: 12236432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
    Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
    Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of a shortened standardised treatment regimen of antituberculosis drugs for patients with multidrug-resistant tuberculosis (STREAM): study protocol.
    Gama E; Madan J; Langley I; Girma M; Evans D; Rosen S; Squire SB
    BMJ Open; 2016 Oct; 6(10):e014386. PubMed ID: 27798041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public health. Responding to market failures in tuberculosis control.
    Gupta R; Kim JY; Espinal MA; Caudron JM; Pecoul B; Farmer PE; Raviglione MC
    Science; 2001 Aug; 293(5532):1049-51. PubMed ID: 11463877
    [No Abstract]   [Full Text] [Related]  

  • 10. The 'frozen state' of drug-resistant tuberculosis: notes from the field in Abkhazia.
    Majumdar S; O'Brien D; Hurtado N; Hewison C; du Cros P
    Intern Med J; 2011 Dec; 41(12):805-8. PubMed ID: 22151949
    [No Abstract]   [Full Text] [Related]  

  • 11. The need for global action against multidrug-resistant tuberculosis.
    Heymann SJ; Brewer TF; Wilson ME; Fineberg HV
    JAMA; 1999 Jun; 281(22):2138-40. PubMed ID: 10367825
    [No Abstract]   [Full Text] [Related]  

  • 12. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey.
    Günther G; Gomez GB; Lange C; Rupert S; van Leth F;
    Eur Respir J; 2015 Apr; 45(4):1081-8. PubMed ID: 25395035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curing multidrug-resistant tuberculosis: not all about the money.
    Gruber K
    Lancet Respir Med; 2016 Nov; 4(11):870-871. PubMed ID: 27799128
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug-resistant tuberculosis: desperate measures?
    Cullinan T
    Lancet; 2001 Apr; 357(9262):1124. PubMed ID: 11297986
    [No Abstract]   [Full Text] [Related]  

  • 15. DOTS plus strategy in resource-poor countries.
    Davies PD
    Int J Tuberc Lung Dis; 1999 Sep; 3(9):843-4. PubMed ID: 10488896
    [No Abstract]   [Full Text] [Related]  

  • 16. How to ensure the continued resurgence of tuberculosis.
    Reichman LB
    Lancet; 1996 Jan; 347(8995):175-7. PubMed ID: 8544556
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidemiological and cost analysis of multidrug-resistant tuberculosis in Oman.
    Mohammadi A; Nassor ZS; Behlim T; Mohammadi E; Govindarajan R; Al Maniri A; Smego RA
    East Mediterr Health J; 2008; 14(6):1240-5. PubMed ID: 19161099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Treatment Cost on Transmission of Multidrug-Resistant Tuberculosis Into Iran.
    Bialvaei AZ; Kafil HS; Asgharzadeh M
    Clin Infect Dis; 2015 Sep; 61(6):1029-30. PubMed ID: 26060290
    [No Abstract]   [Full Text] [Related]  

  • 19. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis.
    Ionescu AM; Mpobela Agnarson A; Kambili C; Metz L; Kfoury J; Wang S; Williams A; Singh V; Thomas A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):677-689. PubMed ID: 30073886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.